 German-listed shares of MorphoSys MOR, -31.96 MOR, 2.44 lost a third of their value on Monday after its partner Roche said an Alzheimer drug trial failed. Roche ROG, -3.76 slumped 4 in Zurich as the company said Phase 3 studies evaluating gantenerumab in people with mild cognitive impairment MCI due to Alzheimers and mild Alzheimers dementia did not meet their primary endpoint of slowing clinical decline. 